Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 9.1× sales vs its 10.4× historical median P/S.
Fair value ≈ $90.65 · price $79.97 today
Undervalued · 12% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$NARI | Primer: Inari Medical (NARI US) - Jan 2026
"Inari Medical is a leader in the minimally invasive treatment of venous thromboembolism (VTE), with a substantial untapped market opportunity..." - αSK (Smartkarma)
Read more: https://www.smartkarma.com/insights/primer-inari-medical-nari-us-jan-2026
@Fallingknife concur - 2025 guidance seems like a difficult objective. I did not like the clarity provided (rather lack of thereof) on how to get to 2025 guidance ~$475m... This is NOT coming from EU. Than interim guy, Fred the attorney plumber NEEDs toGO !
Approvals could push it though for some support...
imo, just like $NARI hit $40 (different business) i theorized, fat management makes for attractive takeout. less than 6 months later acquired by Striker ($SYK) for $80. As nsclc & endometrial advance, it is possible that it may attract buyout interest.
$KAI $NARI $SYK
Kadant to replace Inari Medical in S&P 600 at open on 2/19
Kadant (KAI) will replace Inari Medical (NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker (SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions.
$NARI $SYK Stryker commences $80 per share cash offer for Inari Medical
Stryker (SYK) announced that it is commencing, through a wholly owned subsidiary, Eagle 1 Merger Sub, a cash tender offer to purchase all of the issued and outstanding shares of common stock of Inari Medical (NARI) for $80.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, among Stryker, Eagle 1 Merger Sub, Inc and Inari. The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on February 18, unless extended in accordance with the terms of the merger agreement.
The tender offer is subject to various conditions, including the minimum tender of at least a majority of the issued and outstanding shares of Inari common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is anticipated to close by the end of the first quarter of 2025, as previously announced.
